Remove Heart attacks Remove Medicare Remove Technology
article thumbnail

Bridging the Gap: Enhancing Stroke Recovery Through Digital Health Solutions

DAIC

I had had a heart attack previously. Technology tools are becoming more sophisticated, bidirectional and disease-specific, and are being designed with home care in mind. After the stroke, I had new prescriptions, and this was the first obstacle for me. I couldn’t dispense my medications into daily doses.

Stroke 115
article thumbnail

New Study Reveals 65 and Older Population Lowered Blood Pressure, Cholesterol, and Weight Using Mobile Technology

DAIC

Eighty percent of heart attacks and strokes are preventable. partially because its key risk factor, high blood pressure, is a ‘silent killer,’ and most patients have no symptoms before their first heart attack or stroke. Yet, CVD remains the leading cause of death in the U.S.,

article thumbnail

Cleerly Raises $106 Million in Series C Extension Funding

DAIC

Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. We are very excited to see our purpose-driven mission come to life, making advanced cardiac care accessible to more patients and working towards our goal of eliminating heart attacks.” “We

article thumbnail

AliveCor's Kardia 12L ECG System Receives Category III CPT Codes

DAIC

CPT codes are widely used by government payers, including Medicare and Medicaid, and commercial insurance companies to identify healthcare services and procedures for reimbursement. KAI 12L is the world's first AI to detect 35 cardiac determinations, including heart attacks, using a reduced leadset.

article thumbnail

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. vs. 13.2%, respectively). The CardiAMP HF II trial is expected to similarly secure CMS reimbursement.

article thumbnail

Medtronic Receives CMS National Coverage Analysis for Renal Denervation System

DAIC

13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.

CMS 52